Halozyme Therapeutics in (halo 1 08/15/28)
13F holders, Q2 2026 (June 30)6holders −2
0new positions
2sold out
$1.42avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Halozyme Therapeutics in (halo 1 08/15/28) in their 13F filings, down 2 from Q1 2026. 0 opened new positions and 2 sold out. The largest holders were Absolute Investment Advisers, LLC ($20.4M), Ofi Invest Asset Management ($8.7M) and State of Wisconsin Investment Board ($5.8M).
- Company
- Halozyme Therapeutics in (halo 1 08/15/28)
- CUSIP
- 40637HAF6
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $8.1M |
All 13F filers, Q1 2026 → Q2 2026: 1,000,000 shares bought and 6,404,177 shares sold, net −5,404,177 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Absolute Investment Advisers, LLC | 1.97% | No change | 14,000,000 | $20.4M |
| Ofi Invest Asset Management | 0.09% | No change | 6,800,000 | $8.7M |
| State of Wisconsin Investment Board | 0.01% | Add +33.3% | 4,000,000 | $5.8M |
| Focus Partners Wealth | 0.00% | Reduce -5.2% | 2,175,000 | $3.2M |
| Bank of New York Mellon Corp | 0.00% | Reduce -32.8% | 410,000 | $601K |
| Boussard & Gavaudan Gestion Sas | 0.00% | — | 2,100 | $3K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 1 08/15/28)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 1 08/15/28) the manager owns.